Overall survival (OS) benefit derived from frontline treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer (NSCLC), was further improved after at least 12 months of follow-up, according to results from the phase III CheckMate-9LA trial presented at the 2020 ASCO Virtual Scientific Program.1
“CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival cureves and lower progressive disease rates as best overall response, the hypothesis for (this study) design was validated,” Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, said during a presentation of the results.
The trial found that nivolumab plus ipilimumab combined with…
